Monthly Archives: September 2013

Targeted Medical Pharma to Present at 2013 Aegis Capital Healthcare Conference

September 24, 2013 by Staff
No comments
Los Angeles, CA, September 24th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that the company’s CEO and Chief Science Officer William Shell, M.D. along with President and Chief Operating Officer, David Silver M.D., will be presenting at the Aegis Capital 2013 Healthcare Conference being held at The Encore at Wynn Hotel in Las Vegas, Nevada on Friday, September 27, 2013 at 11:30 a.m. in Room 1. The conference will feature more than 45 healthcare companies from around the world and will feature presentations Continue reading →

Targeted Medical Pharma to Present at 2013 Rodman & Renshaw Annual Global Investment Conference

September 5, 2013 by Staff
No comments
Los Angeles, CA, September 5th, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced that the company’s CEO and Chief Science Officer William Shell, M.D., will be presenting at the 2013 Rodman & Renshaw Annual Global Investor Conference being held at the Millennium Broadway Hotel, New York, on Monday, September 9, 2013 at 11:40 a.m. EST. The conference will feature more than 200 public & private companies from around the world and is expected to present to an audience of over 1,500 attendees. The Continue reading →

Targeted Medical Pharma Initiates Clinical Trial of Red Blood Cell Stimulating Formulation

September 4, 2013 by Staff
No comments
Medical Food Designed to Address the Increased Nutritional Requirements of Anemia    Los Angeles, CA, September 4, 2013 — Targeted Medical Pharma, Inc. (OTCQB: TRGM), today announced  the company has initiated a third open-label clinical trial of its oral amino acid-based erythropoietin stimulating system (ESS) to determine increased red blood cell production in subjects diagnosed with anemia of chronic disease. The study consists of 30 patients randomized for treatment across multiple independent sites to measure the changes in blood values after the oral administration of Continue reading →